ArticleHospital pharmacy2016
Probable Tapentadol-Associated Serotonin Syndrome After Overdose.
Article in Hospital pharmacy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Tapentadol Immediate Release (IR) versus Morphine Hydrochloride for Postoperative Analgesia of Patients Undergoing Total Abdominal Hysterectomy-A Prospective Cohort Study.Medicina (Kaunas, Lithuania) · 2023Observational
- Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.Drug design, development and therapy · 2023Review
- Multimechanistic Single-Entity Combinations for Chronic Pain Control: A Narrative Review.Cureus · 2022Review
- Fever in a patient with osteomyelitis: the diagnosis could be serotonin syndrome.BMJ case reports · 2021Article
- Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques.Therapeutic advances in psychopharmacology · 2019Article
- Tapentadol: an overview of the safety profile.Journal of pain research · 2019Review
- Spontaneously reported adverse drug events related to tapentadol and oxycodone/naloxone in Australia.Therapeutic advances in drug safety · 2018Article
- Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.Advances in therapy · 2018Review
- Cardiac Arrest Following Drug Abuse with Intravenous Tapentadol: Case Report and Literature Review.The American journal of case reports · 2017Review
- Comment on "Probable Tapentadol-Associated Serotonin Syndrome After Overdose".Hospital pharmacy · 2017Article
- Comment on Tapentadol and Serotonin Syndrome.Hospital pharmacy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDrug-induced serotonin syndrome is a potentially life-threatening condition. An Ovid MEDLINE, and PubMed search from 1950 to October 2015 revealed one published case report of suspected tapentadol-induced serotonin syndrome. We report a probable case of tapentadol-induced serotonin syndrome after overdose. CASE SUMMARY: A 48-year-old male was found unresponsive after a witnessed overdose of medications including tapentadol. After administration of naloxone by emergency medical services, the patient became combative and presented with altered mental status. He was managed with physical and pharmacologic restraints in the emergency department. Other medications that could be implicated in the patient's presentation include duloxetine and amitriptyline. It was suspected that the opioid properties of tapentadol were masking the patient's signs and symptoms of serotonin syndrome. The patient was admitted to the medical intensive care unit, remained stable, and was discharged 2 days later. Currently, there is one published case report of suspected tapentadol-induced serotonin syndrome after an overdose. The manufacturer of tapentadol reported no cases of serotonin syndrome during clinical trials, but there have been postmarketing cases reported with co-administration of other serotonergic drugs.
conclusionWe report a probable case of tapentadol-induced serotonin syndrome after overdose. Further research is needed to better understand the pharmacology and incidence behind this adverse event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.